baber/WOPTO huggingface dataset:
Patent NZ-500063-A (NZ)
Title: Discharge cap for container having neck portion with movable top portion to break open compartment housing material to be dissolved in container and allow subsequent sealing off or allowing outflow of liquid within container
Inventor: FREDRICK MICHAEL COORY
IPC: B65D81/32
Filed: 1998-03-12
Abstract: A cap (103) is disclosed for a container (2) where a drink, made of two components, can be stored or carried with the components stored separately. The components are mixed prior to the consumption of the drink. The cap (103) includes a collar (106) secured to the container (2) and a top (105) which is in two parts. The top (105) is moveable between an open and a closed position. When the top (5, 105) is initially in the open position, a basket (117) between the top (105) and the liquid initially holds the material (138), which can be a powder or tablet. The top (105) is initially closed to release the seal between the liquid and the material, the drink is shaken, and the top (105) reopened for a passageway from the liquid to the exterior of the cap (103). A cover (4) is releasably secured over the cap (103).
Patent NZ-503162-A (NZ)
Title: Use of a krill- or atlantic cod-derived hydrolase with chymotrypsin, collagenase, elastase and/or exo peptidase activity to inactivate call adhesion components including ICAM-1 (CD54), CD4, CD8, CD11 and CD28.
Inventor: DE FAIRE JOHAN
IPC: C12N9/76
Filed: 1996-02-08
Abstract: The use of a hydrolase derived from krill or Atlantic cod in a medicament to inhibit tissue transplant rejection.  The tissue is treated extra-corporeally prior to transplant into the recipient.  The hydrolase has substantial anti cell-cell adhesion activity by selectively removing or inactivating ICAM-1 (CD54), CD4, CD8, CD11 and/or CD28.  Preferably the hydrolase also has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase activity.
Patent NZ-504511-A (NZ)
Title: Recombinant proteins comprising fused first and second distinct site specific recombinase and use in methods for the integration of foreign DNA into eukaryotic genomes
Inventor: TAGLIANI LAURA A
IPC: C12N9/00
Filed: 1998-11-17
Abstract: A recombinant protein comprising a first site-specific recombinase fused with a second distinct site-specific recombinase.
Patent NZ-504682-A (NZ)
Title: Bio-degradable mineral wool, especially rock wool for thermal and acoustic insulation or soil-less culture substrates, has high alumina and alkali metal oxide contents and can be produced by internal centrifugation
Inventor: BERNARD JEAN-LUC
IPC: C03C13/06
Filed: 1999-09-16
Abstract: Mineral wool capable of dissolving in a physiological medium, which mineral wool comprises the constituents below in the following percentages by weight: SiO2   39-55%, Al2O3   16-27%, CaO   3-35%, MgO   0-15%, Na2O   0-15%, K2O   0-15%, R2O (Na2O + K2O) 10-17%, P2O5   0-3%, Fe2O3   0-15%, B2O3   0-8%, and TiO2   0-3%; and in that MgO is between 0 and 5%, especially between 0 and 2%, when R2O d" 13.0%.
Patent NZ-504975-A (NZ)
Title: Processes of making North American ginseng fractions, products containing them, and use as immunomodulators
Inventor: PANG PETER K T
IPC: A61P43/00
Filed: 1998-12-11
Abstract: A process of preparing ginseng fraction PQ2, the process comprising: a) combining American ginseng with a first solvent comprising an alcohol and heating the resulting solution at a temperature of about 80-100°C for a time period of about 2-4 hours to produce a first ginseng solution; b) thereafter separating the first ginseng solution to produce an alcohol/ginseng solution and a first ginseng residue; c) thereafter combining the first ginseng residue with water and heating the resulting solution at a temperature of about 80-100°C for a time period of about 2- 4 hours to produce a ginseng residue solution; d) thereafter separating the ginseng residue and a first aqueous extract solution containing a first ginseng extract; e) providing a second aqueous extract solution which comprises at least a part of the first ginseng extract, wherein in the second aqueous extract solution the proportion of the first ginseng extract to water is about 1:18 to 1:22; f) thereafter combing the second aqueous extract solution with a second solvent comprising an alcohol, wherein the proportion of the second solvent to water is about 1:1 to 3:5, to produce a first precipitate and a first supernatant; g) thereafter combining the first supernatant produced in step (f) with a third solvent comprising an alcohol, wherein the proportion of the second solvent to water is about 3:2 to 3:1, to produce a second precipitate and a second supernatant; and h) isolating the second precipitate to produce ginseng fraction PQ2. Divisional filed as 529377
Patent NZ-505174-A (NZ)
Title: Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer
Inventor: MADIYALAKAN RAGUPATHY
IPC: A61K39/00
Filed: 1996-05-15
Abstract: A therapeutic composition comprising an effective amount of a binding agent specific for a first epitote on a multi-epitote in vivo antigen present in the host's serum which the antigen does not elicit a host immune response; wherein the binding agent present in the composition is exclusive of B43.13. The binding agent specifically binds to a first epitote on the antigen and forms a binding agent/antigen pair, whereby effective host immune response is elicited against a second epitote on the antigen.
Patent NZ-505193-A (NZ)
Title: Opioid agonist/antagonist combinations
Inventor: KAIKO ROBERT F
IPC: A61K9/22
Filed: 1998-12-22
Abstract: Oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist  and  an orally  active opioid antagonist are described.  The  opioid antagonist  is included in a ratio to the opioid agonist  to provide   a   combination  product  which  is  analgesically effective  when the combination is administered orally,  but which   is  aversive  in  a  physically  dependent  subject. Preferably, the amount of opioid antagonist included in  the combination  product  provides at least  a  mildly  negative "aversive" experience in physically dependent addicts  e.g., precipitated abstinence syndrome.
Patent NZ-507452-A (NZ)
Title: Hygromycin a derivatives
Inventor: GUHAN SUBRAMANIAN SAM
IPC: A61P31/04
Filed: 1999-05-03
Abstract: The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1 and R2 are as defined herein. The compounds of formula (I) are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula (I) and the methods of treating bacterial and protozoal infections by administering the compounds of formula (I).
Patent NZ-514138-A (NZ)
Title: Animal ear tag assembly and component locking member
Inventor: RITCHEY EUGENE B
IPC: A01K11/00
Filed: 2000-12-14
Abstract: An animal ear tag is disclosed which includes a component locking member (12) of novel design. The component locking member (12) has an interior passageway which substantially conforms in shape to the post or pin (63) of an ear tag installation tool to stabilize the connection therebetween which prevents slippage or other undesirable movement of the component locking member when installed on the ear of an animal. The component locking member is characterized by a transverse portion (30) having a pair of opposed flanges (32, 34), and a substantially planar rear edge. The planar edge is adapted for contact with an inner surface of a jaw of an installation tool which further provides stabilization between the component locking member and the ear tag installation tool. As an ear tag assembly, the invention utilizes the component locking member and an ear tag panel (14) having a grommet (20) which engages the component locking member (12).
Patent NZ-515026-A (NZ)
Title: Heterocyclic amidine derivatives useful as prodrugs of thrombin inhibitors
Inventor: BAUCKE DORIT
IPC: A61P25/28
Filed: 2000-04-05
Abstract: A compound or a isomer or salt thereof has the formula (I) wherein: A is R1OOC-CH2-, R1OOC-CH2-CH2-, R1OOC-CH(CH3)-, R1OOC- C(CH3)2-, R1OOC-CH(C2H5)-, alkyl-SO2-(CH2)2-6-, HO3S-(CH2)2- 6-, 5-tetrazolyl-(CH2)1-6-, alkyl-O-(CH2)2-6-, R2R3N-(CH2)2- 6-, R2-S-(CH2)2-6-, R2R3N-SO2-(CH2)2-6-, HO-(CH2)2-6-, R1aS-C(O)-CH2-, R1a-O-C(S)-CH2, R2R3N-C(O)-CH2-, R2R3N-O- C(O)-CH2- or R2N(OH)-C(O)-CH2-; B is a group of formula (2); p is 0 or 1; R4 is H or R9OOC-; R5 is H; R6 is H, alkyl, bicycloalkyl, tricycloalkyl or optionally substituted phenyl, or cycloalkyl where one or two C-C single bonds in the ring can be replaced by a C=C double bond or a phenyl radical can be fused on; R7 is H, alkyl, optionally substituted phenyl or cycloalkyl; R8 is H or CH3; E is a group of formula (II) to (VI); D is a group of formula (VII), (VIII) or IX); X is S or O and Y and Z are independently CH, C-CH3, C-Cl or C-CF3; X is S or O; Y is N and Z is CH, C-CH3, or C-CF3 or X is S or O, Y is CH, C-CH3, or C-CF3 and Z is N; G is H, OH, OR18, C(O)O-R20, SR18 or C(S)S-R20; K is H or G and K together form C(O)O, C(O)S, C(S)S or C(S)O and R1a, R1 to R3, R18, R20 and R9 are as defined in the specification limited by the provisos listed in the specification. The compounds are useful as thrombin inhibitors, anticoagulation and anti-inflammatory agents.
Patent NZ-518041-A (NZ)
Title: Novel enzymes which dehydrate glycerol
Inventor: SEYFRIED MARKUS
IPC: C12N9/88
Filed: 2000-09-22
Abstract: A method of converting glycerol to 1,3-propanediol in a thermophilic Caloramator viterbiensis, the method comprising culturing a thermophilic Caloramator viterbiensis that ferments glycerol to 1,3-propanediol under conditions such that 1,3-propanediol is produced; and a method of producing 1,3-propanediol from glycerol comprising: (a) incubating glycerol with a thermostable dehydratase enzyme derived from a Caloramator viterbiensis; (b) converting the glycerol to 3-hydroxypropionaldehyde; and (c) adding a reducing agent capable of reducing 3-hydroxypropionaldehyde to 1,3- propanediol.
Patent NZ-520316-A (NZ)
Title: Use of compounds of retinoid type for treating bacterial infections caused by bacteria such as straphylococcus aureus
Inventor: VOEGEL JOHANNES
IPC: A61K31/592
Filed: 2001-01-30
Abstract: A use of at least a compound selected among retinoid-type molecules for preparing a composition for preventive or curative treatment of bacterial colonisation, deterioration in pathological conditions caused by said colonisation and secondary skin infections induced by said bacteria and more particularly by the Staphylococcus aureus is disclosed. Also disclosed is a use of at least a compound selected among retinoid-type molecules in a skin cleansing composition, and a cosmetic treatment method for cleaning the skin or correcting its smell by applying said composition on the skin.
Patent NZ-520551-A (NZ)
Title: Method and system for receiving, storing and processing electronic vouchers with a mobile telephone or a personal digital assistant
Inventor: ELHAOUSSINE MEHDI
IPC: G06Q20/00
Filed: 2001-11-21
Abstract: Electronic shopping or discount coupons can be stored in a mobile device such as a mobile phone or PDA. When the person going shopping purchases items the identification codes of the purchased items are read at the payment terminal in the shop and either the list of coupons stored in the mobile is transmitted to the payment terminal or the list of purchased items is transmitted to the mobile. Either way the list of coupons is compared to the list of purchased items and if any item is identified for which the mobile holds a corresponding coupon, the discount in accordance with the coupon information can be deducted from the total purchase price.
Patent NZ-524251-A (NZ)
Title: Modified human adenovirus comprising a non-native polypeptide having altered tropism
Inventor: LINDHOLM LEIF
IPC: A61K35/76
Filed: 2001-07-19
Abstract: A modified virus comprises one or more non-native polypeptides. The polypeptide comprises one or more framework moieties which possesses a folded three dimensional structure each framework moiety containing one or more binding moieties and the polypeptide is capable of being expressed in the cytoplasm and nucleus of a mammalian host cell in a conformation which is maintained in the absence of a ligand for the binding moieties subsequently to bind with the ligand and the polypeptide is capable of transport through the nuclear membrane wherein the modified virus has an altered tropism conferred by the binding moieties. Preferably the on-native polypeptide comprises framework moieties derived from the immunoglobin binding Z-domain from staphylococcal protein A, an immunoglobin binding domain from streptococcal protein G, neck region peptide from lung surfactant protein D. Also disclosed are methods for producing a modified virus, regulating the replication of a modified virus or for assaying the solubility of non-native polypeptide or modified viral protein and use of the modified virus in the preparation of a medicament for the treatment of tumor cells or proliferating cells.
Patent NZ-525095-A (NZ)
Title: Extensible object previewer in a shell browser
Inventor: KURTZ JAMES BRIAN
IPC: G06F9/44
Filed: 2003-04-01
Abstract: A shell browser (file system browser) is configured to display a plurality of items representing multiple item types and comprises a default previewer which provides a standard level of functionality for multiple item types; and an extensibility mechanism which enables functionality beyond the standard level provided by the default previewer for one or more of the multiple item types. The default previewer is a preview control or a preview pane. The multiple item types include multiple file types. The shell browser can further comprise an installed application program which provides the functionality beyond the standard level for at least one item type. The extensibility mechanism includes a set of application programming interfaces (APIs) which enable third party software developers to extend the functionality beyond the standard level. The extended functionality provided by a shell browser can include: a preview control which can provide the user with an image or other visual display of the item being previewed and also may also present the user with controls such as iterator buttons which allow the user to shift the focus from one item to the next by clicking a mouse button; an edit or metadata control which can include a display of key properties of the previewed item and also presents the user with a control for making edits to the metadata and/or a task control contains tasks relevant to the namespace and/or the selection. A shell browser is configured to display a plurality of items representing multiple item types and comprises a first previewer which provides a standard level of functionality for the multiple item types and a second previewer which provides an alternative level of functionality for one or more of the multiple item types. The shell browser is configured to selectively deploy one of the first and second previewers for the one or more item types. The first and second previewers are preview controls or preview panes. The multiple item types include multiple file types. The shell browser can selectively deploys the one previewer in response to an indication from the user or automatically. The second previewer can be an installed application. The shell browser can further comprise a third previewer which provides another alternative level of functionality for one or more of the multiple item types wherein the shell browser is configured to selectively deploy one of the first, second and third previewers for a particular item type.
Patent NZ-530125-A (NZ)
Title: Apparatus and method for the treatment of waste
Inventor: AMES ROY VICTOR
IPC: C02F3/04
Filed: 2003-12-10
Abstract: The present invention relates to a treatment system for treating primary waste onsite. The treatment system includes a separation cone which separates the solid waste from the liquid waste and the different wastes are subsequently treated separately. The solid wastes are subject to aerobic decomposition by worms and other suitable organisms while liquid wastes are filtered through alternate layers of coarse and fine filter media. The resulting treated liquid can be recirculated or pumped out of the system for other purposes or further treatment. The treatment system is designed as a compact modular system and maybe used for the treatment of domestic human waste. Reference has been directed by the Commissioner of Patents under Section 16 to Patent Specification NZ530126 (61) Addition to 530125
Patent NZ-532089-A (NZ)
Title: Installation and use of removable heaters in a hydrocarbon containing formation
Inventor: VINEGAR HAROLD J
IPC: E21B47/022
Filed: 2002-10-24
Abstract: In an embodiment, a system may be used to heat a hydrocarbon containing formation. The system may include a heater placed in an opening in the formation. The system may allow heat to transfer from the heater to a part of the formation. The transferred heat may pyrolyze at least some hydrocarbons in the formation. The heater may be removable from the opening in the formation and redeployable in at least one alternative opening in the formation.
Patent NZ-532836-A (NZ)
Title: A method for treating inflammatory bowel disease
Inventor: CHAROUS LAUREN
IPC: A61K9/22
Filed: 2002-11-12
Abstract: Disclosed is a controlled release and targeted pharmaceutical composition that comprises a pharmaceutically effective amount of an anti-malarial compound and a sustained release excipient or carrier that delays and targets the release of the anti-malarial compound in the gastrointestinal tract. The composition is used in the manufacture of a medicament for the treatment of inflammatory bowel disease.
Patent NZ-533328-A (NZ)
Title: Novel benzothiazine and benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same
Inventor: CORDI ALEX
IPC: A61P25/18
Filed: 2002-12-20
Abstract: Benzothiazine and benzothiadiazine derivative compounds of formula (I), their isomers and addition salts are disclosed, wherein: R1 represents an aryl or heteroaryl; R2 represents hydrogen, halogen or a hydroxy; A represents CR4R5 or NR4; R3 represents hydrogen, (C1-C6)alkyl or (C3-C7)cycloalkyl; R4 represents hydrogen or (C1-C6)alkyl; or A represents a nitrogen and together with the adjacent -CHR3- forms a ring as shown in the specification, wherein m represents 1, 2 or 3; R5 represents hydrogen or halogen. These compounds of formula (I) are useful as AMPA modulators.
Patent NZ-538027-A (NZ)
Title: Novel polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrozol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
Inventor: ZOOK SCOTT E
IPC: C07D487/04
Filed: 2003-08-26
Abstract: Disclosed is a polymorph Form III of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-a]-pyrimidin-7-yl}phenyl)acetamide, and use thereof as a sedative-hypnotic, anxiolytic, anticonvulsant, and/or skeletal muscle relaxant agent. Also disclosed are related compositions comprising these polymorph Form III of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-a]-pyrimidin-7-yl}phenyl)acetamide and their use in the treatment of insomnia.
Patent NZ-538146-A (NZ)
Title: Coatings with at least 2 layers comprising microorganisms that produce amylolytic or proteolytic enzymes enabling enhanced microbial performance
Inventor: POLSENSKI MARTIN J
IPC: A01N63/50
Filed: 2003-07-11
Abstract: A coating with enhanced microbial performance which can be applied to any surface that is subject to growth of unwanted or undesired organisms. The coating comprises of at least two layers which may contain micro-organisms, amylolytic or proteolytic enymes, nutrients and other ingredients which contribute to the microbial performance of each layer.
Patent NZ-539280-A (NZ)
Title: Spray for transmucosal administration of pharmaceuticals for muscular and skeletal disorders
Inventor: DUGGER HARRY A
IPC: A61K39/00
Filed: 2003-08-27
Abstract: Disclosed is a propellant free buccal spray composition for transmucosal administration of a pharmacologically active compound using a polar solvent. The active compound is in an amount of between 0.001 and 60 percent by weight of the total composition and is selected from the group of anti-muscle spasm agents consisting of baclofen, botulinum toxin, carisoprodol, chlorphenesin, chlorzoxazone, cyclobenzaprine, dantrolene, metazalone, methocarbamol, orphenadrine, tizanidine, and mixtures thereof, and muscle relaxants selected from baclofen, carisoprodol, chlorphenesin, chlorzoxazone, cyclobenzaprine, dantrolene metazalone, methocarbamol, orphenadrine and mixtures thereof.
Patent NZ-541946-A (NZ)
Title: Water treatment compositions with masking agent for disinfecting drinking water
Inventor: SOUTER PHILIP FRANK
IPC: A01N65/00
Filed: 2004-02-23
Abstract: A composition for disinfecting contaminated drinking water is disclosed. The composition can include a disinfecting agent for disinfecting or sanitizing the water and a masking agent for masking or minimizing undesired characteristics of the disinfecting agent, such as taste and odor. Particularly disclosed is a composition for disinfecting drinking water, wherein the composition comprises: (a) a halogen-based disinfecting agent such as a chlorine-based disinfecting agent; (b) a halogen-compatible masking agent; and (c) a substrate, wherein the masking agent is loaded onto the substrate. Also disclosed is a method for masking undesired taste and odor characteristics of a disinfecting agent in a volume of water while preserving disinfecting activity of the disinfecting agent, wherein the method comprises: (a) adding an effective amount of a chlorine-based disinfecting agent to water; (b) adding an effective amount of a chlorine-compatible masking agent loaded on to a substrate to the water: and (c) allowing an effective amount of the masking agent to be released from the substrate to mask the undesired taste and odor of the disinfecting agent in the water. The halogen-compatible masking agent can be a chlorine-compatible masking agent or flavorant, such as a citrus fruit derived flavor. The substrate can be a clay, zeolite, water-soluble carrier, water-insoluble carrier, or mixtures thereof. The flavorant can be loaded onto the substrate. The composition can include other components, such as a primary coagulant, a coagulant aid, a bridging flocculant, a polymeric material, an alkali agent, an autocatalytic oxidant, and mixtures thereof.
Patent NZ-546610-A (NZ)
Title: Road safety barrier
Inventor: BOWYER STEVEN
IPC: E01F15/04
Filed: 2006-04-18
Abstract: A road safety barrier formed from a series of beam sections (10) supported by posts is disclosed. The beams include predefined post attachment locations and the positions of successive posts along the length of the barrier are varied relative to the centres of the beam sections. The strength or flexibility of the barrier may be tailored at various regions by the spacing of the posts.